CSIRTS // UNIFIED SECURITY ADVISORY FEEDSYS ● ONLINE · POWERED BY INTELFUSIONS.COM

CVE-2026-50243: In NLnet Labs Unbound 1.6.2 up to and including 1.25.1, when Unbound is configured with the 'respip' module in front of the validator together with a 'response-ip' redirect rule or

lowCVSS 3.7CVE-2026-50243
In NLnet Labs Unbound 1.6.2 up to and including 1.25.1, when Unbound is configured with the 'respip' module in front of the validator together with a 'response-ip' redirect rule or an RPZ file with an RPZ-IP trigger, the rewriting handler does not check the security status of the upstream answer and can instead rewrite a BOGUS A/AAAA answer to point to an operator's configured IP. If the validator finds an expired or otherwise invalid RRSIG on an answer whose A record falls within a 'response-ip'/RPZ configuration, the answer is still rewritten and given a hard coded security level of INSECURE. This results in the client receiving an INSECURE NOERROR reply rewritten by the operator's configured IP. A malicious actor can exploit the possible poisonous effect by spoofing a BOGUS A/AAAA answer that falls inside the operator's configured subnet rewrites. Such DNSSEC protected answers are then insecurely redirected to the operator's configured target.

Details

Source
NVD Recent CVEs (US · database · site)
Severity
low — CVSS 3.7
Published
2026-07-22
Last updated
2026-07-24
Exploitation
Not in CISA KEV at last sync

Original advisory: https://nvd.nist.gov/vuln/detail/CVE-2026-50243

Exploitation outlook

EPSS (FIRST.org) estimates each CVE’s probability of exploitation in the next 30 days — here is the CSIRTS.com read on those numbers.

Referenced CVEs

CVECSIRTS overviewExternal
CVE-2026-50243coverage & exploitation statusNVD · CVE.org

Same CVEs, other sources

How other CERTs, PSIRTs and databases cover the vulnerabilities in this advisory.

Recent advisories for In NLnet Labs

A cluster of recent advisories against the same product widens the attack surface — attackers routinely chain freshly published CVEs on one product, so review these together.

More from NVD Recent CVEs